Cite
HARVARD Citation
Naing, A. et al. (2021). CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. Journal for immunotherapy of cancer. 9 (7), p. . [Online].